Fig. 1

cDMARDs: conventional disease-modifying antirheumatic drugs; MTX: methotrexate; LFN: leflunomide; SSZ: sulfasalazine; CSP: cyclosporine; NSAIDs: nonstreroidal antiinflammatory drugs; DAPSA: Disease Activity Index for Psoriatic Arthritis; MDA: minimal disease activity; VLDA: very low disease activity; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; bDMARDs: biologic disease-modifying antirheumatic drugs; tsDMARDs targeted synthetic disease modifying antirheumatic drugs; TNFi: TNF-alpha inhibitor; ADA: adalimumab, CTZ: certolizumab pegol; ETN: etanercept; GOL: golimumab; IFX: infliximab; IL-17i: IL-17 inhibitor; IXE: ixekizumab; SEC: secukinumab; IL-12/23i: IL-12/23 inhibitors; UST: ustekinumab; IL-23i: IL-23 inhibitor; GUS: guselkumab; ABA: abatacept; TOF: tofacitinib. 1. Analgesics, NSAIDs and intra-articular corticosteroid infiltrations can be used in all stages, when necessary. 2. Preferably use TNFi or IL-17i if there are axial manifestations; IL-23i or IL-17i or IL-12/23i if significant psoriasis; monoclonal TNFi if recurrent uveitis; TNFi (IFX, ADA, CTZ) or IL-12/23i if concomitant active Crohn’s disease; TNFi (IFX, ADA, GOL) or IL-12/23i or JAKi (TOF) if concomitant active ulcerative colitis. 3. Preferably use IL-17i if significant psoriasis; monoclonal TNFi if recurrent uveitis; TNFi (IFX, ADA, CTZ) if concomitant active Crohn's disease; TNFi (IFX, ADA, GOL) if concomitant active ulcerative colitis